Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status

Haematologica. 2021 Dec 1;106(12):3215-3218. doi: 10.3324/haematol.2021.278779.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Fluorodeoxyglucose F18
  • Humans
  • Multiple Myeloma* / diagnostic imaging
  • Multiple Myeloma* / pathology
  • Neoplasm, Residual
  • Positron Emission Tomography Computed Tomography*
  • Positron-Emission Tomography
  • Radiopharmaceuticals


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18